Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
April 3, 2024
- Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
- Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
- FPMAJ Lays Out Planned Activities for FY2024
March 22, 2024
- Scrap Off-Year Drug Revision as It Mars Innovation, Supply: JPMA Official
March 22, 2024
- Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
March 21, 2024
- Biosafety Rules Tied to Gene Therapy Put Heavy Financial Burden on Hospitals: Expert
March 19, 2024
- Doctors’ Groups Call for Cross-Ministerial Efforts to Spur Genomic Medicine
March 18, 2024
- JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
February 19, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Payers, HCPs Hail First Step Taken for Generic Industry Revamp in FY2024 Reform
February 15, 2024
- Drug Supply Worsens for 3rd Month Running amid Flu Surge, Shipment Halts
February 13, 2024
- JGA Issues Written Reprimand to Sawai over GMP Issues
January 30, 2024
- JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
January 25, 2024
- Around 70 APIs Right Now Are Good Candidates for Rx-to-OTC Switches: JSMI Chair
January 24, 2024
- Japan Needs National Efforts to Boost Biosimilar Production: Kameda Chief Pharmacist
January 22, 2024
- Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs
January 19, 2024
- JPMA Calls for Setting Broad Spillover Exclusions in Market Expansion Re-Pricing
January 19, 2024
- 80-90% of Clinics in Northern Noto Not Functioning: JMA Official
January 12, 2024
- Wholesalers Ask for Prioritized Drug Supply for Disaster Areas; Emergency Dispensing Scheme Begins
January 11, 2024
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…